Efficacy and Safety of Coenzyme Q10 in the Treatment of Statin-Associated Myalgia
NCT ID: NCT00590408
Last Updated: 2009-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE4
10 participants
INTERVENTIONAL
2006-03-31
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CoEnzyme Q10 in Statin Myopathy
NCT01140308
Effectiveness of Creatine in Preventing Muscle Aching From Cholesterol-Lowering Statin Drugs
NCT00797407
Muscle Characteristics Associated With Statin Therapy
NCT00990834
Metabolic Features of Post-Myopathy Patients Associated With Statin Treatment
NCT01040650
7T Magnetic Resonance Spectroscopy and Skeletal Muscle Biopsy Findings in Statin Associated Adverse Muscle Events
NCT04507373
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
coenzyme Q10
60mg capsule twice daily for 12 weeks
2
matching placebo
matching placebo capsule twice daily for 12 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
coenzyme Q10
60mg capsule twice daily for 12 weeks
matching placebo
matching placebo capsule twice daily for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients currently taking coenzyme Q10 (or have taken in the previous 30 days)
* Patients receiving concomitant niacin, fibric acid derivatives, bile acid sequestrants, or other drugs that effect cholesterol levels or interact with statins
* Patients with a history of alcoholism or malnutrition
* Patients who have had acute coronary syndrome or muscle trauma in the prior 7 days
* Patients with a history of chronic muscle/joint pain, fibromyalgia, or degenerative disk disease.
19 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Creighton University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Creighton University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robyn Kondrack, PharmD
Role: PRINCIPAL_INVESTIGATOR
Creighton University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Cardiac Center of Creighton University Medical Center
Omaha, Nebraska, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
05-13642
Identifier Type: -
Identifier Source: secondary_id
05-13642
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.